AVR Anteris Technologies Global Corp.
USHealthcareAs of 2026-07-10 16:00
Why AVR matters now
Anteris Technologies Global Corp. (AVR) is a US stock in Healthcare. The latest InvestLog snapshot shows $9.77 with +2.95% on the session and $359.4M in market capitalization; recent performance reads 1-month +27.01% and YTD +95.99%.
The latest financial table shown here is Q1 2026, with revenue of $494.0K, net income of $-23.0M, and EPS of $-0.93. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -24.1%.
The latest indexable market news headline is "Pennon returns to profit after water bill hikes" from Proactive Investors - Finance.
Additional event context on this page matters because analyst consensus is Buy with a median target of $16.50; recent insider activity includes Roberts David B filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.83
P/S
194.38
EV/EBITDA
-0.86
DCF Value
$-0.96
FCF Yield
-24.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
28.3%
Operating Margin
-5192.9%
Net Margin
-5148.8%
ROE
-124.4%
ROA
-32.3%
ROIC
-34.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $494.0K | $-23.0M | $-0.93 |
| Q4 2025 | $310.0K | $-29.2M | $-1.24 |
| FY 2025 | $1.9M | $-94.1M | $-4.00 |
| Q3 2025 | $429.0K | $-22.2M | $-0.94 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$16.50
Target (Median)
$16.50
Target Range
$15.00 - $18.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
AU
Exchange
—
Beta
0.73
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.